Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Current population screening for vascular disease is neither efficient nor effective. Peter Elwood and colleagues believe we should have a public information strategy highlighting the benefits (and risks) of aspirin for older people, but Colin Baigent argues that the evidence of benefit is not yet strong enough

More information Original publication

DOI

10.1136/bmj.330.7505.1440

Type

Journal article

Publication Date

2005-06-18T00:00:00+00:00

Volume

330

Pages

1440 - 1441

Total pages

1

Keywords

Aged, Aspirin, Fibrinolytic Agents, Humans, Middle Aged, Myocardial Infarction, Risk Factors